Employee
Valthos
Valthos provides an AI‑driven platform that continuously analyzes genomic, proteomic, and epidemiological data to detect emerging biological threats in real time. The system automatically generates and ranks candidate therapeutics and vaccine designs, and offers synthesis planning and risk assessment dashboards to accelerate countermeasure development for government biodefense agencies, public‑health organizations, and pharmaceutical companies.
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
Updated 5 months ago
Funding
Raised to date
$30MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Public health agencies and pharmaceutical developers struggle to detect emerging biological threats quickly and to design effective medical countermeasures at the speed required to prevent widespread outbreaks.
Solution
Valthos leverages advanced artificial‑intelligence models to analyze genomic, proteomic, and epidemiological data in real time, flagging potential pathogens and biothreat agents as they appear. The platform automatically generates candidate therapeutic and vaccine designs, prioritizing molecules with high predicted efficacy and safety. By integrating rapid in‑silico screening with automated synthesis planning, Valthos shortens the timeline from threat identification to countermeasure development. Results are delivered through a secure web interface that provides risk scores, actionable insights, and downloadable design files for downstream laboratory validation.
Target Audience
Primary customers are governmental biodefense agencies, public‑health organizations, and pharmaceutical companies responsible for rapid response to emerging infectious diseases.
Features
- Real‑time AI‑driven surveillance that ingests global sequencing and outbreak reports to detect anomalous biological signatures
- Generative models that propose antibody, small‑molecule, and vaccine candidates tailored to the identified threat
- Automated synthesis route planning and feasibility scoring to accelerate laboratory implementation
- Risk assessment dashboards with quantitative threat scores, confidence intervals, and recommended response actions
- Secure API for integration with existing public‑health information systems and pharmaceutical R&D pipelines